Combining PD-L1 blockade with resiquimod reduces tumor size, activates DCs, diminishes Treg cells, and boosts the CD8+ T cell/Treg cell ratio in the TME in mice tumor models (134). The gene discussed is CD274; the disease is neoplasm.